SCHEMBL1923883

SCHEMBL1923883

Clc1nc(Nc2ccccc2)nc(Nc2ccccc2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
MAPK1 P28482 1/20 1.00
NFKB1 P19838 3/20 0.91
LMNA P02545 1/20 0.81
NPC1 O15118 1/20 0.73
RAB9A P51151 1/20 0.73
CA12 O43570 2/20 0.67
CA1 P00915 2/20 0.67
CA2 P00918 2/20 0.67
CA9 Q16790 2/20 0.67
GAA P10253 2/20 0.63
KDM4E B2RXH2 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.58
KCNH3 Q9ULD8 3/20 0.57
POLB P06746 1/20 0.55
TSHR P16473 1/20 0.53
RECQL P46063 1/20 0.53
MCL1 Q07820 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL113103 0.95 NFKB1 (1.00) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL21655135 0.95 NFKB1 (1.00) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL3499751 0.92 MAPT (0.85) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL23643402 0.91 NFKB1 (0.92) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL27617353 0.90 MAPT (0.81) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL11885185 0.90 LMNA (1.00) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL8909557 0.90 MAPT (0.81) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL17577161 0.89 MEN1 (0.79) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL1925527 0.89 MEN1 (0.79) MAPTMEN1KMT2AMAPK1NFKB1
SCHEMBL633400 0.88 MEN1 (0.77) MAPTMEN1KMT2AMAPK1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072856-A1 LPAAT-beta inhibitors and uses thereof CELL THERAPEUTICS, INC. (US) 2007-03-29 US claimed
US-6235819-B1 Process to scavenge amines in polymeric compounds by treatment with triazine derivatives and compositions therefrom BRIDGESTONE CORPORATION (JP) 2001-05-22 US claimed
US-6063873-A RUBBER TREAD STOCK COMPRISING A VULCANIZABLE COMPOSITION FREE OF METAL REINFORCEMENT, AND A TRIAZINE COMPOUND OF GIVEN FORMULA WHICH ACTS AS AN AMINE SCAVENGER WITHOUT HAVING A DELETERIOUS EFFECT UPON THE VULCANIZABLE COMPOSITION BRIDGESTONE CORPORATION (JP) 2000-05-16 US claimed
EP-0927740-A2 Process to scavenge amines in polymeric compounds by treatment with triazine derivates, and compositions therefrom Bridgestone Corporation (JP) 1999-07-07 EP claimed
EP-0927744-A2 Process to scavenge amines in polymeric compounds by treatment with triazine derivates, and compositions therefrom Bridgestone Corporation (JP) 1999-07-07 EP claimed
US-4563189-A WOOL AND COTTON WOOL DEVELOPMENT INTERNATIONAL LTD. (GB) 1986-01-07 US claimed
CN-119465445-B Preparation method of halogen-free flame-retardant high-strength alginate fiber 山东海纤生物材料科技有限公司 2025-04-15 CN disclosed
CN-119465445-A Preparation method of halogen-free flame-retardant high-strength alginate fiber 山东海纤生物材料科技有限公司 2025-02-18 CN disclosed
CN-116102509-A Difluoromethylthioether compound, and preparation method and application thereof 浙江工业大学 2023-05-12 CN disclosed
EP-2417129-B1 TRIAZINE-ARYL-BIS-INDOLES AS PDE-4 INHIBITORS USEFUL FOR THE TREATMENT OF ASTHMA COUNCIL SCIENT IND RES (IN) 2016-03-23 EP disclosed
US-9085559-B2 Triazine-aryl-bis-indoles and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-07-21 US disclosed
US-9085559-B2 Triazine-aryl-bis-indoles and process for preparation thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2015-07-21 US disclosed
US-20120283263-A1 TRIAZINE-ARYL-BIS-INDOLES AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-11-08 US disclosed
US-5561131-A INCREASING THE WOOL GROWTH BY ADMINISTERING AN ANTIPROTOZOA AGENT TO SHEEP MALLINCKRODT VETERINARY, INC. (US) 1996-10-01 US disclosed
EP-0661976-A1 DEFAUNATION METHOD MALLINCKRODT VETERINARY LIMITED (AU) 1995-07-12 EP disclosed
WO-1995012585-A1 TEXTILE TREATMENT UNIVERSITY OF LEEDS (GB) 1995-05-11 WO disclosed
EP-0661976-A4 DEFAUNATION METHOD. MALLINCKRODT VETERINARY LTD (AU) 1994-07-20 EP disclosed
WO-1994000513-A1 SUBSTITUTED PYRIMIDINES AND SUBSTITUTED TRIAZINES AS RUBBER-TO-METAL ADHESION PROMOTERS UNIROYAL CHEMICAL COMPANY, INC. (US) 1994-01-06 WO disclosed
WO-1993002680-A1 DEFAUNATION METHOD PITMAN-MOORE AUSTRALIA LIMITED (AU) 1993-02-18 WO disclosed
US-3931165-A INSECTICIDES, HERBICIDES BARER SOL J 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283263-A1 TRIAZINE-ARYL-BIS-INDOLES AND PROCESS FOR PREPARATION THEREOF AHR, IDO2, IDO1 MAPT 2931/4885MEN1 3647/4885KMT2A 997/4885
US-20070072856-A1 LPAAT-beta inhibitors and uses thereof LPCAT3, LPCAT1, PLAAT2 MAPT 2807/4885MEN1 2590/4885KMT2A 326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.